-
Competing-risks model for prediction of small-for-gestational-age neonate from biophysical and biochemical markers at 11-13 weeks' gestation.
Papastefanou I, Wright D, Syngelaki A, Souretis K, Chrysanthopoulou E, Nicolaides KH.
Ultrasound Obstet Gynecol 2021;57:52-61. pdf -
Ophthalmic artery Doppler in combination with other biomarkers in the prediction of pre-eclampsia at 35-37 weeks' gestation.
Sarno M, Wright A, Vieira N, Sapantzoglou I, Charakida M, Nicolaides KH.
Ultrasound Obstet Gynecol 2021;57:600-606. pdf -
Prediction of imminent preeclampsia at 35-37 weeks gestation.
Ciobanu A, Wright A, Panaitescu A, Syngelaki A, Wright D, Nicolaides KH.
Am J Obstet Gynecol 2019;220:584.e1-584.e11. pdf -
Biomarkers of impaired placentation at 35-37 weeks' gestation in the prediction of adverse perinatal outcome.
Ciobanou A, Jabak S, De Castro H, Frei L, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2019;54:79-86. pdf -
Screening for pre-eclampsia at 35-37 weeks' gestation.
Panaitescu A, Ciobanu A, Syngelaki A, Wright A, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2018;52:501-506. pdf -
Development of pre-eclampsia within 4 weeks of sFlt-1/PlGF ratio > 38: comparison of performance at 31-34 vs 35-37 weeks' gestation.
Dragan I, Wright D, Fiolna M, Leipold G, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;49:209-212. pdf -
Repeat measurements of uterine artery pulsatility index, mean arterial pressure and serum placental growth factor at 12, 22 and 32 weeks in the prediction of preeclampsia.
Andrietti S, Carlucci S, Wright A, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;49:751-755. pdf -
Screening for pre-eclampsia using sFlt-1/PlGF ratio cut-off of 38 at 30-37 weeks' gestation.
Dragan I, Georgiou T, Prodan N, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;49:73-77. pdf -
Competing-risks model in screening for pre-eclampsia by maternal factors and biomarkers at 35-37 weeks' gestation.
Andrietti S, Silva M, Wright A, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;48:72-9. pdf -
Prediction of stillbirth from biochemical and biophysical markers at 11-13 weeks.
Mastrodima S, Akolekar R, Yerlikaya G, Tzelepis T, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;48:613-7. pdf -
Biophysical and biochemical markers at 35-37 weeks' gestation in the prediction of adverse perinatal outcome.
Valiño N, Giunta G, Gallo DM, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:203-9. pdf -
Biophysical and biochemical markers at 30-34 weeks' gestation in the prediction of adverse perinatal outcome.
Valino N, Giunta G, Gallo DM, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:194-202. pdf -
Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 30-34 weeks' gestation.
Tsiakkas A, Saiid Y, Wright A, Wright D, Nicolaides KH.
Am J Obstet Gynecol 2016;215:87.e1-87.e17. pdf -
Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 19-24 weeks' gestation.
Gallo DM, Wright D, Casanova C, Campanero M, Nicolaides KH.
Am J Obstet Gynecol 2016;214:619.e1-619.e17. pdf -
Contingent Screening for Small by Weight for Gestational Age Neonates.
Frick AP, Nicolaides KH, Poon LC.
Pediatr Endocrinol Rev 2016;13:568-73. -
Competing risks model in screening for preeclampsia by biophysical and biochemical markers at 30-33 weeks' gestation.
Garcia-Tizon Larroca S, Tayyar A, Poon LC, Wright D, Nicolaides KH.
Fetal Diagn Ther 2014;36:9-17. pdf -
Competing risk model in screening for preeclampsia by mean arterial pressure and uterine artery pulsatility index at 30-33 weeks' gestation.
Tayyar A, Garcia-Tizon Larroca S, Poon LC, Wright D, Nicolaides KH.
Fetal Diagn Ther 2014;36:18-27. pdf -
Longitudinal changes in uterine artery Doppler and blood pressure and the risk of preeclampsia.
Khalil A, Garcia-Mandujano R, Maiz N, Elkhaouli M, Nicolaides KH.
Ultrasound Obstet Gynecol 2014;44:197-204. -
A competing risks model in early screening for preeclampsia.
Wright D, Akolekar R, Syngelaki A, Poon LC, Nicolaides KH.
Fetal Diagn Ther 2012;32:171-8. -
Maternal serum resistin at 11 to 13 weeks' gestation in normal and pathological pregnancies.
Nanda S, Poon LC, Muhaisen M, Acosta IC, Nicolaides KH.
Metabolism 2012;61:699-705.